Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
February 27, 2024 07:00 ET
|
Purple Biotech Ltd.
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024...